Richter Acquires Janssen’s Evra Transdermal Contraceptive Patch Assets for $263.5M Published: Dec 3, 2020 | Tags: Asset Purchase Agreement, Evra, Gedeon Richter, Janssen Pharmaceutical, Signs, Transdermal Contraceptive Patch Assets, Treat […]readmore
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded […]readmore
Shots: Mycenax to get $5M upfront and will get $16.5M as total deal value in four installments. Richter to get exclusive WW rights to develop, manufacture and commercialize biosimilar tocilizumab […]readmore
Copyright © 2020 Digiqole. All Right Reserved.